Jie He, MD
Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1124259353
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 896 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.
Across 896 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- Lilly USA, LLC$4K
- Sanofi-aventis U.S. LLC$2K
- AstraZeneca$2K
- Amneal Pharmaceuticals LLC$2K
- Corcept Therapeutics$1K
- plus $11K from 52 others
What the payments were for
- Food & beverage$25,970100%
- Education$370%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$1,058
- Wegovy$732
- FARXIGA$727
- Korlym$578
- SOLIQUA 100/33$521
- TEZSPIRE$371
- Kerendia$363
- DEXCOM G7 GSS (161)$350
- Vemlidy$347
- iLet Bionic Pancreas$305
- REZDIFFRA$269
- JARDIANCE$223
- Omnipod$152
- FREESTYLE LIBRE 3$138
- ZEGALOGUE$125
- AREXVY$125
- APTIOM$125
- Prolia$125
- Livdelzi$125
- VOQUEZNA$125
How this compares
$26,067 in reported general payments places this provider in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 420 | $559,204 |
| OzempicSemaglutide | 208 | $379,381 |
| ProliaDenosumab | 198 | $338,046 |
| Tresiba Flextouch U-200Insulin Degludec | 357 | $319,302 |
| JardianceEmpagliflozin | 226 | $259,572 |
| MounjaroTirzepatide | 176 | $234,632 |
| TradjentaLinagliptin | 284 | $171,823 |
| KerendiaFinerenone | 104 | $108,613 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 56 | $73,608 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 102 | $71,022 |
| FarxigaDapagliflozin Propanediol | 77 | $69,645 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $54,088 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 64 | $42,539 |
| Bydureon BciseExenatide Microspheres | 17 | $27,249 |
| RybelsusSemaglutide | 18 | $23,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $3,872 | $793,836596 claims |
| Boehringer IngelheimJardiance, Tradjenta | $508 | $431,395510 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $4,064 | $416,597239 claims |
| AmgenProlia | $737 | $338,046198 claims |
| BayerKerendia | $871 | $108,613104 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $2,448 | $73,60856 claims |
| AstraZenecaFarxiga | $1,648 | $69,64577 claims |
| MerckJanumet Xr | $96 | $42,53964 claims |
| AbbVieSynthroid | $920 | $9,883137 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $1,634 | $7,436269 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Rockville
- David BrownRockville$497K
- Helena RodbardRockville$468K
- Gerti TashkoRockville$106K
- Monika MannanRockville$8K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- Philip LevinBaltimore$489K
- Roy PhillipsBel Air$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.